Last edition
News about "Androgen Deprivation Therapy "
US FDA Expands Approval of Novartis' Pluvicto for Earlier Treatment of Advanced Prostate Cancer
The US FDA has approved Novartis' Pluvicto for use in patients with PSMA-positive metastatic hormone-sensitive prostate cancer, expanding access to the radioligand therapy at an earlier stage of disease.
Androgen Deprivation Therapy | 03/08/2026 | By News Bureau
US FDA Recommends AstraZeneca's TRUQAP for PTEN-Deficient Prostate Cancer
US Food and Drug Administration (FDA) advisory panel backs TRUQAP (capivasertib) with abiraterone and ADT for PTEN-deficient metastatic hormone-sensitive prostate cancer, based on positive phase 3 CAPItello-281 results showing favorable benefit-risk.
Androgen Deprivation Therapy | 01/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy